Premium
Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post‐transplantation
Author(s) -
Koh KyungNam,
Im Ho Joon,
Suh Jin Kyung,
Lee Seong Wook,
Choi Eun Seok,
Seo Jong Jin
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25351
Subject(s) - brentuximab vedotin , medicine , transplantation , oncology , anaplastic large cell lymphoma , hematopoietic stem cell transplantation , stem cell , refractory (planetary science) , lymphoma , chemotherapy , autologous stem cell transplantation , antibody drug conjugate , cd30 , monoclonal antibody , immunology , antibody , physics , biology , astrobiology , genetics
Brentuximab vedotin (BV) is a monoclonal antibody‐drug conjugate that targets CD30, and has been reported to be effective for relapsed/refractory anaplastic large cell lymphoma. We here report a patient who experienced multiple relapses after conventional chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). He achieved a complete metabolic response with BV and proceeded to undergo haploidentical HSCT. After HSCT, he received three doses of BV to prevent an early relapse, and remains in remission 16 months post‐transplantation. Our case suggests the potential use of BV both as a bridging therapy to allogeneic HSCT and as a maintenance therapy post‐transplantation. Pediatr Blood Cancer 2015;62:1063–1065. © 2015 Wiley Periodicals, Inc.